Clinical trial
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients…
NCT00295932 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00295932 |
|---|---|
| Title | Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL) |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH Rutgers Cancer Institute of New Jersey Columbia University Emory University |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | rituximab, bortezomib, cyclophosphamide, prednisone |
| Enrollment | 79 |
| Start date | Dec 13, 2005 |
| Primary completion | Mar 11, 2018 |
| Completion | Mar 11, 2018 |
| First posted | Feb 24, 2006 |
| Last update posted | Nov 20, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: